About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
F
2021 ADA Highlights: SURPASS Program: Change in HbA1C From Baseline
By
Francesco Giorgino
2 Videos
906 views
July 14, 2021
2 Comments
Login to view comments.
Click here to Login
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Related Content
AUTOPLAY
ON
National Lipid Association
2024 NLA Scientific Sessions
Thu, May 30, 2024
The American Society for Preventive Cardiology
ASPC 2024 Congress on CVD Prevention
Fri, Aug 2, 2024
34:49
Scripps Health
Medications for Weight Loss: The New Satiety Hormones
Feat.
K. Fujioka
15:06
Robert Busch
GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!
12:26
Juan Frias
SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide
59:34
Scripps Health
Obesity Treatment: The Essentials (2024 Update)
Feat.
S. Harris
26:32
Practical Ways to Achieve Targets in Diabetes Care
Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity
Feat.
S. Nissen
20:24
Diana Isaacs
Tirzepatide for Type 2 Diabetes
44:41
Norman Lepor
Obesity: New Understanding and Treatments
26:49
Diana Isaacs
Tirzepatide Updates
05:08
Susan Brian
The Differences Between the Products of GLP1's and GLP/GIPs
06:31
Susan Brian
Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist
36:34
Scripps Health
GLP-1 Hysteria
Feat.
S. Harris
13:33
Dr. Sharmila Ghimire
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesi…
Feat.
D. Ghimire
05:40
Susan Brian
An Introduction to Tirzepatide for Weightloss
59:30
Scripps Health
Primary Care Literature Update: 2022/2023
Feat.
J. Diamant
49:21
McMaster University Department of Medicine
Semaglutide: Where Are We Now and Where Are We Going?
Feat.
S. Boushahri,
D. Lazzam,
K. MacEachern
13:43
Stanford Medicine
What's the Ideal Therapy for Obesity?
Feat.
A. Yeoh
37:10
Diana Isaacs
Clinical Pearls & Updates on Incretins: The Diabetes Drugs Takin…
66:59
UT Health San Antonio School of Medicine
Effective Treatment of T2DM Requires Combination Therapy
Feat.
R. DeFronzo
20:17
AHA 2023 Insights
AHA 2023 Insights: Optimizing the Use of SGLT2is, GLP-1 RAs and Non-…
Feat.
F. Zannad
42:39
Primary Care Education Consortium
A Pathophysiologic Approach for Treating Type 2 Diabetes: Part 3
Feat.
J. Gavin Iii
